FIELD: chemistry.
SUBSTANCE: invention relates to a 2-pyridone compound represented by formula [1]: 
, a tautomer of said compound, a pharmaceutically acceptable salt thereof (hereinafter referred to as a 2-pyridone compound, a tautomer of the compound or a pharmaceutically acceptable salt thereof, referred to as "2-pyridone compound or related compounds". Invention also relates to a crystalline 3-cyclopropyl-6-{(1R)-1-[4-(1,1-difluoroethyl)phenyl]-2-[(2R)-5-oxo-pyrrolidin-2-yl]-ethyl}pyridin-2(1H)-one, method for production thereof, to a medicament for the prevention or treatment of a disease or condition that can be improved by the effect of glucokinase activation.
EFFECT: technical result is obtaining a novel 2-pyridone compound having the properties of a glucokinase activator, which can be used as a medicament for the prevention or treatment of diabetes.
7 cl, 3 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 2-PYRIDONE DERIVATIVES | 2010 |
|
RU2551847C2 |
| NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | 2010 |
|
RU2567755C2 |
| (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | 2012 |
|
RU2681211C2 |
| PYRAZOLE COMPOUNDS SUBSTITUTED BY HETEROARYL AND THEIR APPLICATION IN PHARMACEUTICS | 2019 |
|
RU2805312C2 |
| CYCLOALKYL NITRILE PYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | 2014 |
|
RU2655380C2 |
| AMINOTETRAHYDROPYRANES AS DIPEPTIDYLPEPTIDASE-IV INHIBITORS FOR TREATING OR PREVENTING DIABETES | 2010 |
|
RU2550508C2 |
| CARBOXAMIDE COMPOUNDS AND USING THEM AS CALPAIN INHIBITORS | 2010 |
|
RU2540856C2 |
| CYCLOPROPYLAMIDE DERIVATIVES AS N-HISTAMINE RECEPTOR MODULATORS | 2007 |
|
RU2449989C2 |
| CATHEPSIN CYSTEINE PROTEASE INHIBITORS | 2014 |
|
RU2692799C2 |
| (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | 2012 |
|
RU2668952C2 |
